Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : An analysis of the Swedish Lymphoma Registry
(2017) In British Journal of Haematology 177(3). p.449-456- Abstract
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20+ lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival,... (More)
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20+ lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0·033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P < 0·00005), as did 10-year survival, 53% vs. 72% (multivariate P = 0·027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.
(Less)
- author
- Molin, Daniel ; Linderoth, Johan LU and Wahlin, Björn Engelbrekt
- publishing date
- 2017-02-24
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Gender differences, Nodular lymphocyte predominant Hodgkin lymphoma, Population-based analysis, Rituximab, Survival
- in
- British Journal of Haematology
- volume
- 177
- issue
- 3
- pages
- 449 - 456
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85013797108
- pmid:28233899
- ISSN
- 0007-1048
- DOI
- 10.1111/bjh.14567
- language
- English
- LU publication?
- no
- id
- f1d460a6-1694-4cd3-a657-b01df9443c91
- date added to LUP
- 2017-03-09 13:38:46
- date last changed
- 2024-03-31 05:44:23
@article{f1d460a6-1694-4cd3-a657-b01df9443c91, abstract = {{<p>Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20<sup>+</sup> lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0·033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P < 0·00005), as did 10-year survival, 53% vs. 72% (multivariate P = 0·027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.</p>}}, author = {{Molin, Daniel and Linderoth, Johan and Wahlin, Björn Engelbrekt}}, issn = {{0007-1048}}, keywords = {{Gender differences; Nodular lymphocyte predominant Hodgkin lymphoma; Population-based analysis; Rituximab; Survival}}, language = {{eng}}, month = {{02}}, number = {{3}}, pages = {{449--456}}, publisher = {{Wiley-Blackwell}}, series = {{British Journal of Haematology}}, title = {{Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : An analysis of the Swedish Lymphoma Registry}}, url = {{http://dx.doi.org/10.1111/bjh.14567}}, doi = {{10.1111/bjh.14567}}, volume = {{177}}, year = {{2017}}, }